-transparent.png){kind=logo}
Ten patients with systemic mycoses, including five with fungal meningitis, were treated with intravenously or intrathecally administered miconazole, or both. Minimal inhibitory concentrations of miconazole for clinical isolates of Coccidioides immitis, Cryptococcus neoformans and Candida albicans were less than 0.6 microg per ml. Except for pruritus of variable degrees, the drug was well tolerated both intravenously and intrathecally by all patients. No measurable impairment of renal, hepatic or bone marrow function was observed in patients after 4(1/2) months of intravenous therapy. No hematological or biochemical abnormalities and no evidence of recurrent coccidioidal osteomyelitis were observed in 16 months of follow-up in our first patient treated with this drug. Miconazole is apparently an effective antifungal drug of low toxicity and is a potentially useful agent for treatment of human systemic mycoses.
J P Sung, and
J G Grendahl, and
H B Levine
October 1977,
The New England journal of medicine,
J P Sung, and
J G Grendahl, and
H B Levine
March 1977,
Modern medicine of Asia,
J P Sung, and
J G Grendahl, and
H B Levine
August 1979,
Chest,
J P Sung, and
J G Grendahl, and
H B Levine
February 1979,
Lancet (London, England),
J P Sung, and
J G Grendahl, and
H B Levine
January 1977,
Proceedings of the Royal Society of Medicine,
J P Sung, and
J G Grendahl, and
H B Levine
February 1985,
Sabouraudia,
J P Sung, and
J G Grendahl, and
H B Levine
December 1977,
Fortschritte der Medizin,
J P Sung, and
J G Grendahl, and
H B Levine
January 1981,
Orvosi hetilap,
J P Sung, and
J G Grendahl, and
H B Levine
July 1979,
Archives of internal medicine,
J P Sung, and
J G Grendahl, and
H B Levine
September 1988,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
